

# 16 | Programme overview

---

9.00-10.00 **Registration and welcome tea & coffee**

---

10.00-10.05 **Welcome and introduction**

---

Tuke Hall

10.05-12.00 **Session 1: Development of gene editing technologies**

---

Tuke Hall

**Chairs**

Ivana Barbaric; *University of Sheffield*  
Versha Prakash; *Royal Holloway University of London*

---

10.05-10.35 **INV01: SNPing in and out of stem cell-cardiomyocytes with Cas9/CRISPR**  
Chris Denning; *University of Nottingham*

---

10.35-11.10 **INV02: The self-inactivating Kamicas9 system for CNS gene editing**  
Nicole Déglon; *University of Lausanne*

---

11.10-11.25 **OR01: Universal antibody-mediated cell therapy (uACT)**  
Annie Etuk; *University College London*

---

11.25-11.40 **OR02: Highly efficient delivery and transfection of gene loaded polymer nanoparticles by novel GET peptide**  
Aveen Jalal; *University of Nottingham*

---

11.40-12.05 1 minute rapid poster presentations (11 posters)

---

12.05-13.15 **Lunch and exhibition**

---

## 12.15-13.15 Posters

---

12.15-12.45 Posters: even numbers

---

12.45-13.15 Posters: odd numbers

---

## 13.15-15.00 Session 2: Disease modelling with gene edited cells

Tuke Hall

### Chairs

Sian Harding; *Imperial College London*

Nora Clarke; *Imperial College London*

---

13.15-13.45 **INV03: hiPSC disease modelling in engineered heart tissue format**

Arne Hansen; *University Medical Center Hamburg-Eppendorf*

---

13.45-14.15 **INV04: Exploiting induced pluripotent stem cell-derived macrophages as a cellular system to study host-pathogen interactions**

Amy Yeung; *Wellcome Sanger Institute, Hinxton*

---

14.15-14.45 **INV05: Applications of iPSC retinal organoids in disease modelling and therapeutics**

Amelia Lane; *University College London*

---

14.45-15.00 **OR03: CRISPR/Cas9 genome editing in human pluripotent stem cell-cardiomyocytes provides a platform for modeling hypertrophic cardiomyopathy**

Diogo Mosqueira; *University of Nottingham*

---

15.00-15.30

Tea break and posters

# 18 | Programme overview

15.30-17.00

## Session 3: Gene editing and translation

Tuke Hall

### Chairs

Uta Griesenbach; *Imperial College London*

Robyn Bell; *Imperial College London*



Boehringer  
Ingelheim

15.30-15.55

### INV06: Genome engineered T cells for blood malignancies

Waseem Qasim; *University College London*

15.55-16.20

### INV07: Gene therapy for spinal muscle atrophy

Mimoun Azzouz; *University of Sheffield*

16.20-16.45

### INV08: Producing megakaryocytes from iPSCs at GMP grade for clinical-grade platelet production

Moyra Lawrence; *University of Cambridge*

16.45-17.00

### OR04: Targeted gene therapy for treatment of X-linked agammaglobulinemia (XLA)

Catarina Cunha-Santos; *University College London*

17.00-17.15

Short comfort break

17.15-18.00

## Keynote session

Tuke Hall

### Chairs

Peter Andrews; *University of Sheffield*

Saqlain Suleman; *Brunel University*

### KN01: Gene editing of human embryos

Kathy Niakan; *The Francis Crick Institute, London*

18.00-18.15

## Presentation of awards and close of conference

18.15-21.00

## Networking drinks

Tuke Common Room

+++  
ENVIGO

**P01**

**Restoration of normoglycemia in diabetic models via insulin gene therapy**

Asha Recino  
*University of Cambridge*

**P02**

**Comparison of AAV1 and AAV5 viral vector serotypes and four promoters for viral transduction of the corticospinal tract**

Bart Nieuwenhuis  
*University of Cambridge*

**P03**

**Rapid purification of adenovirus vectors avoiding CsCl gradient ultracentrifugation**

Saqilain Suleman  
*Brunel University London*

**P04**

**Intracellular siRNA delivery using silicon nanoneedle arrays**

Ioanna Mylonaki  
*Imperial College London*

**P05**

**CRISPR-CAR lentiviral vector coupling transgene expression with targeted Cas9 cleavage for the engineering of universal T Cells**

Roland Preece  
*University College London*

**P06**

**Optimisation of HEK293T Culture for improved gene therapy manufacture**

Angharad Evans  
*Loughborough University*

**P07**

**Isogenic pairs of patient-derived hiPSC-CMs with an apical hypertrophic cardiomyopathy / left ventricular non-compaction-associated ACTC1 E99K mutation unveil differential functional deficits**

Thomas Owen  
*Imperial College London*

**P08**

**CRISPR/Cas9 genome editing of RDEB mutation hotspot**

Gaetano Naso  
*University College London*

**P09**

**Using bioluminescent hiPSC reporter lines and high content screening to identify novel compounds for cardiomyocyte maturation**

Elizabeth Scott  
*University of Nottingham*

**P10**

**Vector-free hiPSCs for facilitate transfer to clinical practice**

Irena Koutna  
*St. Anne's University Hospital Brno*

**P11**

**Epicardial cell transfection with cationic polymeric nanocomplexes**

Liliana Brito  
*Imperial College London*

**P12**

**Research beyond borders**

Matthias Duechs  
*Boehringer Ingelheim, Biberach an der Riss*